BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ivonescimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ivonescimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05689853-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT05689853)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: Study of AK119 Combined With A
 K112 in Patients With Advanced Solid Tumors\nEstimated primary completion:
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivone
 scimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05689853
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767527-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767527)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: AK112 or Placebo Plus Nab-Paclit
 axel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Tr
 iple-negative Breast Cancer\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06767527
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070466-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07070466)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab in Comb. With FOLFOX
  in Advanced HER2 Neg. GEA\nEstimated primary completion: 1 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07070466
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06750952-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06750952)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab Combined with Chemot
 herapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a 
 Prospective\, Single Arm\, Phase II Trial\nEstimated primary completion: 2
 0 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivon
 escimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06750952
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646055-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06646055)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: AK112 and Cadonilimab Combined
  With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06646055
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086326-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07086326)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Che
 motherapy in Resectable NSCLC\nEstimated primary completion: 30 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07086326
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05227664-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT05227664)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of AK117/AK112 in Metast
 atic Triple-Negative Breast Cancer\nEstimated primary completion: 30 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052
 27664
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05229497-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT05229497)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Phase Ib/II Study of AK112 i
 n Combination With AK117 in Advanced Malignant Tumors\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05229497
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769295-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06769295)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemother
 apy in Patients with NSCLC\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06769295
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769971-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06769971)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Phase II Study of Ivonescimab an
 d Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06769971
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820762-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06820762)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Irinotecan Liposome(II) Combined
  With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A 
 Prospective\, Single-arm\, Multicenter Clinical Study\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06820762
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793332-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06793332)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: BrAin Metastasis in tripLe Negat
 eive Breast Cancer: IvoneScimab and Trop2 ADC\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06793332
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208773-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07208773)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors\nEstimate
 d primary completion: January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07208773
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06196697-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06196697)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: AK104 in Combination With AK112 
 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Ca
 ncer\nEstimated primary completion: January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06196697
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06601335-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06601335)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Phase 3 Study of AK112 Plus AK
 117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous
  Cell Carcinoma (R/M HNSCC)\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06601335
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951503-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06951503)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: A
 K112 and Chemotherapy in First-line Metastatic Colorectal Cancer\nEstimate
 d primary completion: 13 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06951503
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07385001-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07385001)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Prospective\, Multicenter\, 
 Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel 
 and Cisplatin as Neoadjuvant Therapy for ESCC\nEstimated primary completio
 n: 28 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 vonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07385001
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070479-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07070479)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Combination Therapy for PD-1 Res
 istant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adapti
 ve Phase II Trial\nEstimated primary completion: 30 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07070479
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650825-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT07650825)
DESCRIPTION:Ivonescimab\, phase 1.\nStudy: OVV-01 Intravenous and Intratumo
 ral Injection Combined With AK112 for the Treatment of Advanced Solid Tumo
 rs\nEstimated primary completion: 31 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07650825
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357220-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07357220)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Study of AK112 in Combinatio
 n With VG2025 in Colorectal Cancer With Liver Metastases\nEstimated primar
 y completion: 28 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07357220
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162714-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07162714)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: SCRT Followed by AK112 in pMMR/M
 SS Mid-low Rectal Cancer\nEstimated primary completion: 31 March 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07162714
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925724-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06925724)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of Ivonescimab in People
  With Endometrial and Cervical Cancers\nEstimated primary completion: Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06925
 724
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936644-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06936644)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A M
 ulticenter\, Single-arm Phase II Study to Evaluate the Efficacy and Safety
  of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-
 line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patien
 ts With KRAS G12C Mutation\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06936644
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06938321-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06938321)
DESCRIPTION:Ivonescimab\, phase 1/2\, Biliary Tract Cancer.\nStudy: A Study
  of AK130 in Combination With AK112 for the Treatment of Advanced Biliary 
 Tract Cancer\nEstimated primary completion: May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06938321
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07009925-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07009925)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Pacl
 itaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.\n
 Estimated primary completion: May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07009925
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928389-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06928389)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Can
 cer\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06928389
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052253-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07052253)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Clinical Study of AK1
 04/AK112 in Combination With TT-00420 Tablet for Advanced HCC.\nEstimated 
 primary completion: 10 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07052253
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655570-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270511
DTEND;VALUE=DATE:20270512
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07655570)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Pilot Study of Ivonescimab in Ad
 vanced/Metastatic Cutaneous Angiosarcoma\nEstimated primary completion: 11
  May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 655570
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06953999)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Phase III Study of Ivonescimab
  + Chemo With/Without AK117 in Metastatic Pancreatic Cancer\nEstimated pri
 mary completion: 14 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06953999
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590531-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07590531)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
 MT-116 in Combination With AK112 in Patients With Lung Cancer\nEstimated p
 rimary completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07590531
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990620-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT06990620)
DESCRIPTION:Ivonescimab\, phase 1.\nStudy: TACE Plus Ivonescimab for Unrese
 ctable Non-Metastatic HCC\nEstimated primary completion: June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06990620
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06848842-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06848842)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab Plus Chemotherapy in
  Patients With Initially Unresectable Colorectal Cancer Liver Metastases\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06848842
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07488572-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07488572)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Safety and Efficacy of Yiwoxidan
  Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Car
 cinoma Who Are Intolerant to TKI Treatment: a Prospective\, Single Arm\, P
 hase II Clinical Study\nEstimated primary completion: 1 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07488572
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980077-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270617
DTEND;VALUE=DATE:20270618
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06980077)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab for the Treatment of
  Thymic Cancer\nEstimated primary completion: 17 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06980077
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188103-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07188103)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab Plus Short-Course Hy
 pofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous
  Cell Carcinoma\nEstimated primary completion: 30 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07188103
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244965-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07244965)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Neoadjuvant Ivonescimab Plus Che
 motherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Ad
 vanced Cervical Cancer\nEstimated primary completion: 1 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07244965
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630077-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07630077)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tra
 stuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally
  Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abn
 ormalities\nEstimated primary completion: 1 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07630077
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06805617-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06805617)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase 2 Trial of Ivonescimab f
 or Patients With Advanced\, Metastatic Salivary Gland Cancers\nEstimated p
 rimary completion: 1 July 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06805617
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791148-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06791148)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Low-dose Radiotherapy Combined W
 ith Chemotherapy and AK112 as Second-line Treatment in Patients With Advan
 ced G/GEJ Cancer\nEstimated primary completion: 10 July 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06791148
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06537011-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06537011)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: AK112 Plus AP Regimen for Operab
 le Locally Advanced Head and Neck Squamous Cell Carcinoma\nEstimated prima
 ry completion: 15 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06537011
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363408-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT07363408)
DESCRIPTION:Ivonescimab\, phase 1\, Metastatic Colorectal Cancer.\nStudy: I
 vonescimab and ADG126\, Alone\, and in Combination With Leucovorin and Flu
 orouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Ad
 vanced/Metastatic Colorectal Cancer\nEstimated primary completion: 21 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073634
 08
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07114315-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07114315)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of AK130 in Combination 
 With AK112 for the Treatment of Advanced Pancreatic Cancer\nEstimated prim
 ary completion: August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07114315
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07094685-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07094685)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab Before Surgery for t
 he Treatment of Resectable Stage II-IV Head and Neck Cancer\nEstimated pri
 mary completion: 1 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07094685
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06529718-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06529718)
DESCRIPTION:Ivonescimab\, phase 2\, Biliary Tract Cancer.\nStudy: Testing I
 vonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients\nEstima
 ted primary completion: 3 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06529718
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06790212-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06790212)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Neoadjuvant CAPOX Plus Ivonescim
 ab Versus CAPOX for Locally Advanced Colon Cancer\nEstimated primary compl
 etion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06790212
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669779-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07669779)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small C
 ell Lung Cancer\nEstimated primary completion: 30 August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07669779
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846346-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06846346)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Testing Ivonescimab in Combinati
 on With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Ad
 enocarcinoma\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06846346
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591090-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07591090)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Study of AK146D1 Comb
 ined With AK112 in Advanced Breast Cancer\nEstimated primary completion: 1
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivon
 escimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07591090
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339839-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07339839)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: G
 lecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-
 mutated NSCLC\nEstimated primary completion: 30 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07339839
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229417-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07229417)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Trial Evaluating the Efficacy 
 of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negativ
 e or Triple Negative Invasive Lobular Carcinoma\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07229417
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686030-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06686030)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Combination Therapy of AK112 Wit
 h Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer\nEstim
 ated primary completion: October 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06686030
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204548-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07204548)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  IVO-LUNG Study\nEstimated primary completion: October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07204548
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021950-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07021950)
DESCRIPTION:Ivonescimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: A
 K112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment
  of MSS/pMMR Metastatic Colorectal Cancer\nEstimated primary completion: 3
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivone
 scimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07021950
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683846-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06683846)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab in the Treatment of 
 Multiple Advanced Tumors\nEstimated primary completion: 30 November 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06683846
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241819-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07241819)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Ad
 juvant Therapy for Resectable Non-small Cell Lung Cancer\nEstimated primar
 y completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07241819
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245446-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07245446)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of Ivonescimab in First-
 Line ES-SCLC\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07245446
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07017673-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07017673)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Phase II Trial of Ivonescimab in
  Combination With Carboplatin + Docetaxel in Patients With Early-Stage Tri
 ple Negative Breast Cancer\nEstimated primary completion: December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07017673
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057791-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07057791)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Phase II Study of Platinum/Etopo
 side Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer\nEstimate
 d primary completion: December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07057791
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06684873-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06684873)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A M
 ulticenter\, Single-arm\, Open-label Study Evaluating the Safety and Effic
 acy of AK112 Combined With Chemotherapy as First-line Treatment for Non-sq
 uamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO
  BRAIN)\nEstimated primary completion: 1 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06684873
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760520-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06760520)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Short-course Radiotherapy Follow
 ed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer\nEstimated 
 primary completion: 20 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06760520
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603791-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07603791)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Clinical Study to Evaluate the Safety\, Tolerability\, Pharmacokinet
 ics and Antitumor Activity of ALK202 for Injection in Combination With Dru
 gs in NSCLC Participants.\nEstimated primary completion: 30 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07603791
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647016-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07647016)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Trastuzumab Deruxtecan Plus ivon
 escImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer
  Study\nEstimated primary completion: 30 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07647016
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06424626-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT06424626)
DESCRIPTION:Ivonescimab\, phase 1.\nStudy: A Trial of AK104 or AK112 in Com
 bination With Axitinib in Patients With Metastatic Mucosal Melanoma\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06424626
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899086-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT07899086)
DESCRIPTION:Ivonescimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cel
 l Lung Cancer\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07899086
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07103447-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07103447)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Prospective Multicenter Single-a
 rm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07103447
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374250-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07374250)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Perioperative Ivonescimab Plus S
 -1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinom
 a\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07374250
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489703-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07489703)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SHR
 -A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07489703
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244978-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07244978)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Neoadjuvant Ivonescimab（AK112
 ） Combined With Chemotherapy in Patients With Resectable Esophageal Squa
 mous Cell Carcinoma\nEstimated primary completion: 31 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07244978
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Fudan University Shanghai Cancer
  Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650838-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07650838)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: OVV-01 Injection Combined With A
 K112 Injection for the Treatment of Patients With Advanced Soft Tissue Sar
 coma (STS)\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07650838
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742956-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07742956)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Clinical Study to Evaluate the Safety\, Tolerability\, Pharmacokinet
 ics and Antitumor Activity of ALK201 for Injection in Combination With Ivo
 nescimab Injection in sqNSCLC Participants.\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iv
 onescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07742956
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07809893-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07809893)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivosidenib Plus mFOLFOXIRI and C
 elecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal
  Cancer Patients\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07809893
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472478-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07472478)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemoth
 erapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07472478
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06875076-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06875076)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Multicenter Single-Arm Study of 
 Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesot
 helioma\nEstimated primary completion: January 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06875076
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669051-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07669051)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in A
 dvanced Non-small Cell Lung Cancer With Gradual or Potential Progression A
 fter EGFR-TKIs Treatment\nEstimated primary completion: 1 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07669051
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940518-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280119
DTEND;VALUE=DATE:20280120
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06940518)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Phase II Trial of Ivonescimab in
  Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
 \nEstimated primary completion: 19 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06940518
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672575-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06672575)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Phase I/II Study of IVONESCI
 MAB in Recurrent Glioblastoma\nEstimated primary completion: 31 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06672575
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844422-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280218
DTEND;VALUE=DATE:20280219
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06844422)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: Adapted Guided Stereotactic Bo
 dy Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug I
 vonescimab for Pancreatic Cancer (ASCEND)\nEstimated primary completion: 1
 8 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivon
 escimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06844422
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06913218-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT06913218)
DESCRIPTION:Ivonescimab\, phase 1.\nStudy: A Study of mRNA Vaccines AK154 M
 onotherapy or in Combination With AK104/AK112\,and Sequential mFOLFIRINOX 
 in Surgically Resected PDAC\nEstimated primary completion: 23 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06913218
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405190-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07405190)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab Alone And With Carboplatin/Pemetrexed For NSCLC\nEstimated primar
 y completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07405190
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06877650-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06877650)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: First-in-Human Investigation o
 f JMT108 Injection in Participants With Advanced Malignant Tumors\nEstimat
 ed primary completion: 30 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06877650
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07394218-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07394218)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: ctDNA-guided Treatment Decision-
 making\nEstimated primary completion: 31 March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07394218
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412262-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07412262)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Chidamide Combined With Ivonescimab in the Treatment of Advanced N
 on-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherap
 y and High Yes-associated Protein (YAP) Expression\nEstimated primary comp
 letion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07412262
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535463-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07535463)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Ivonescimab\, Chemotherapy\, and Stereotactic Radiosurgery for P
 eople With Non-Small Cell Lung Cancer\nEstimated primary completion: April
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075354
 63
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535437-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07535437)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in Peopl
 e With Non-Small Cell Lung Cancer\nEstimated primary completion: April 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07535437
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767514-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767514)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients With High PD-L1\nEstimated primary completion: April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06767514
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904300-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06904300)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab (AK112) Plus Paclita
 xel as Second-line Therapy in Patients With Advanced G/GEJ Cancer\nEstimat
 ed primary completion: 30 April 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06904300
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743138-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07743138)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: STOMP OUT: A Phase 2 Study To Ev
 aluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic
  Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paragangl
 ioma (PPGL)\nEstimated primary completion: 1 May 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07743138
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594522-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280512
DTEND;VALUE=DATE:20280513
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07594522)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Ivonescimab in People With Non-Small Cell Lung Cancer\nEstimated
  primary completion: 12 May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07594522
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228832-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT07228832)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: P
 hase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patie
 nts With Metastatic Colorectal Cancer\nEstimated primary completion: 31 Ma
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07228
 832
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560124-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07560124)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Study of AK138D1 Alone or in
  Combination With Ivonescimab in Advanced Breast Cancer\nEstimated primary
  completion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07560124
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623356-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280618
DTEND;VALUE=DATE:20280619
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07623356)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non
 -Small Cell Lung Cancer\nEstimated primary completion: 18 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07623356
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868732-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT06868732)
DESCRIPTION:Ivonescimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Eva
 luation of JSKN016 Combination Therapy in Subjects With NSCLC\nEstimated p
 rimary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06868732
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929663-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT06929663)
DESCRIPTION:Ivonescimab\, phase 1.\nStudy: A Study of AK146D1 as Monotherap
 y and in Combination With AK104 or AK112\, in the Treatment of Advanced So
 lid Tumors\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06929663
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767994-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07767994)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: AK112 Combined With GAP Conversi
 on Therapy for Locally Advanced Gallbladder Cancer\nEstimated primary comp
 letion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07767994
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614646-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT07614646)
DESCRIPTION:Ivonescimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Eva
 luate the Safety\, Tolerability\, and Preliminary Efficacy of EVM14 in Com
 bination With Ivonescimab in Sq-NSCLC Patients\nEstimated primary completi
 on: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivones
 cimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07614646
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158489-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07158489)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ove
 rcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab
  in Advanced NSCLC\nEstimated primary completion: July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07158489
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951646-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06951646)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: ctD
 NA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC Wi
 th Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)\nEst
 imated primary completion: 1 July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06951646
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959550-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06959550)
DESCRIPTION:Ivonescimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: P
 hase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patient
 s With Previously Treated Metastatic Colorectal Cancer\nEstimated primary 
 completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06959550
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Precision Treatment of Recurrent
 /Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEstimated
  primary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636772-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280824
DTEND;VALUE=DATE:20280825
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07636772)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Study of AK146D1 Mono
  or Combined With AK112 in Advanced Urothelial Carcinoma\nEstimated primar
 y completion: 24 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07636772
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130240-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07130240)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab Combined With Paclit
 axel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy 
 in Stage IB2 and IIA1 Cervical Cancer\nEstimated primary completion: 31 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 130240
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158840-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07158840)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: AK1
 12 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actiona
 ble Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase 
 Inhibitor (TKI) Treatment\nEstimated primary completion: September 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07158840
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06567314-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06567314)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Phase 2 Study of Ivonescimab in 
 Patients With Cutaneous Squamous Cell Carcinoma\nEstimated primary complet
 ion: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06567314
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854600-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07854600)
DESCRIPTION:Ivonescimab\, phase 2\, Biliary Tract Cancer.\nStudy: A Phase I
 I Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conver
 sion Therapy for Biliary Tract Cancer\nEstimated primary completion: Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0785
 4600
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07936578-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07936578)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in t
 he Treatment of Advanced Non-small Cell Lung Cancer\nEstimated primary com
 pletion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07936578
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885319-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07885319)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: Efficacy and Safety of Ivonesc
 imab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant
  Pleural Mesothelioma\nEstimated primary completion: 30 November 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07885319
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393555-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07393555)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tre
 atment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alt
 erations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP T
 reatment Trial)\nEstimated primary completion: 30 November 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07393555
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819591-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07819591)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Paclitaxel Polymeric Micelles Pl
 us Ivonescimab in Recurrent or Refractory SCLC\nEstimated primary completi
 on: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07819591
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226544-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281205
DTEND;VALUE=DATE:20281206
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07226544)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Ivonescimab Prior to Surgery for
  the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer\nEstima
 ted primary completion: 5 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07226544
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381075-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07381075)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Clinical Trial of Ant
 i-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Check
 point Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanc
 ed Head and Neck Squamous Cell Carcinoma\nEstimated primary completion: 31
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivone
 scimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07381075
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765433-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 2/3 readout est. (NCT07765433)
DESCRIPTION:Ivonescimab\, phase 2/3\, Biliary Tract Cancer.\nStudy: Testing
  the Addition of Ivonescimab Combined With Standard Chemotherapy Compared 
 to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Ad
 vanced Biliary Tract Cancer\nEstimated primary completion: 31 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07765433
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010263-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT07010263)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Study of AK112 as Consolidatio
 n Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Hav
 e Not Progressed Following Concurrent Chemoradiation Therapy\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07010263
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05899608-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT05899608)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05899608
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977542-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06977542)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Neoadjuvant Therapy With Ivonesc
 imab Combined With Chemotherapy for Triple-Negative Breast Cancer\nEstimat
 ed primary completion: January 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06977542
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06814067-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290210
DTEND;VALUE=DATE:20290211
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06814067)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Phase II Multi-centered Study of
  Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of 
 Care (SOC) in Patients with Resectable\, Locally Advanced Head and Neck Sq
 uamous Cell Carcinoma\nEstimated primary completion: 10 February 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06814067
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712094-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290227
DTEND;VALUE=DATE:20290228
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07712094)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: AK112 Combination Therapy as Fir
 st Line Treatment for Metastatic Digestive System Neuroendocrine Cancer\nE
 stimated primary completion: 27 February 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07712094
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536141-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT05536141)
DESCRIPTION:Ivonescimab\, phase 1.\nStudy: A Phase 1 Study of AB521 Monothe
 rapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tum
 ors\nEstimated primary completion: March 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05536141
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516925-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07516925)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of Ivonescimab in People
  With Leiomyosarcoma\nEstimated primary completion: April 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07516925
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877194-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07877194)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Clinical Study of Ivonescimab 
 in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer\nE
 stimated primary completion: 12 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07877194
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619339-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Ivonescimab: Phase 1 readout est. (NCT07619339)
DESCRIPTION:Ivonescimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cance
 r\nEstimated primary completion: May 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07619339
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients Wit
 h Solid Tumors\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917481-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07917481)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Clinical Study Evaluating the 
 Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients Wi
 th Advanced Hepatocellular Carcinoma\nEstimated primary completion: June 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07917481
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602855-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07602855)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Study of Risvutatug Rezeteca
 n in Combination With Ivonescimab in Participants With Advanced Solid Tumo
 rs (EMBOLD PanTumour-103)\nEstimated primary completion: 22 June 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07602855
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359456-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07359456)
DESCRIPTION:Ivonescimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: T
 esting Ivonescimab in Combination With Chemotherapy in Patients With Metas
 tatic Colorectal Cancers Without Liver Metastases\nEstimated primary compl
 etion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 vonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07359456
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264075-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT07264075)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: Study Comparing Ivonescimab Alon
 e or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for 
 the Treatment of SCCHN\nEstimated primary completion: May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07264075
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941583-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07941583)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of Ivonescimab Combined With Iza-bren in Patients With Advan
 ced Non-Small Cell Lung Cancer.\nEstimated primary completion: 1 June 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07941583
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815665-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Ivonescimab: Phase 2/3 readout est. (NCT07815665)
DESCRIPTION:Ivonescimab\, phase 2/3.\nStudy: A Study of Ivonescimab in Comb
 ination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfor
 tumab Vedotin in Metastatic Urothelial Carcinoma\nEstimated primary comple
 tion: 31 October 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07815665
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Per
 sonalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT01042379
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565389-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07565389)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Evaluating Ivonescimab in PD-1 R
 esistant Recurrent or Metastatic Nasopharyngeal Carcinoma\nEstimated prima
 ry completion: May 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07565389
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753824-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20311128
DTEND;VALUE=DATE:20311129
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07753824)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Study of Ivonescimab 
 Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metas
 tatic Appendiceal Adenocarcinoma (AA)\nEstimated primary completion: 28 No
 vember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonesci
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07753824
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234877-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07234877)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Ch
 emotherapy in NSCLC Brain Mets\nEstimated primary completion: January 2032
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07234877
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743632-2023@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07743632)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Neoadjuvant Angiogenesis-Targeti
 ng Bispecific Chemoimmunotherapy for TNBC\nEstimated primary completion: D
 ecember 2032. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonesc
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07743632
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
